ResultsIQ

ResultsIQ › Latest results › Entero Healthcare Solutions Limited

Entero Healthcare Solutions Limited Q3 FY26 earnings call summary

NSE: ENTERO · BSE: 544122

Earnings call of 13 Feb 2026, summarised by AI from the filing.

Net working capital days improved to 61 days in Q3 FY26 from 66 days in Q1 FY26.

Key takeaways

  1. Change Net working capital days improved to 61 days in Q3 FY26 from 66 days in Q1 FY26.
  2. Driver MedTech acquisitions to add ₹1,000 cr annualized revenue and improve margins.
  3. Risk MedTech acquisitions have higher cost structures, which may offset gross margin gains.

Original filing on BSE

Entero Healthcare Solutions Limited Q1 FY27 results

As filed: Revenue ₹1,941 cr (+38% year on year), EBITDA ₹97.0 cr (+94% year on year), PAT ₹52.1 cr (+74% year on year), EBITDA margin 5.0% (+144 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹1,910 cr (+43% year on year), EBITDA ₹86.0 cr (+79% year on year), PAT ₹45.1 cr (+46% year on year), EBITDA margin 4.5% (+92 bps). Score 85 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend; profit growth was below it. EBITDA margin rose 92 bps year on year. Profit lagged EBITDA because of depreciation, interest or other income, not the business. Revenue grew on the previous quarter, against its usual seasonal pattern. Profit rose ₹14.1 cr on a year ago, more than the ₹10.0 cr it added the year before. Share price after the results: −13.8% in 30 days (Nifty 500: +0.9%).
  • Q3 FY26: Revenue ₹1,707 cr (+26% year on year), EBITDA ₹67.8 cr (+38% year on year), PAT ₹33.9 cr (+25% year on year), EBITDA margin 4.0% (+37 bps). Score 36 of 100, Below trend. Revenue and profit before exceptional items growth were below the company's own trend; EBITDA growth was well below it. EBITDA margin rose 37 bps year on year. Consolidated profit +17% but standalone -93%. Revenue rose ₹348 cr on a year ago, against ₹366 cr the year before. Share price after the results: −12.4% in 29 days (Nifty 500: −9.6%).
  • Q2 FY26: Revenue ₹1,571 cr (+21% year on year), EBITDA ₹62.0 cr (+48% year on year), PAT ₹37.0 cr (+42% year on year), EBITDA margin 4.0% (+72 bps). Score 73 of 100, Above trend. EBITDA margin rose 72 bps year on year. Consolidated profit +42% but standalone -60%. Not enough history for a trend yet: scored on growth alone. Share price after the results: −12.2% in 30 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹1,404 cr (+28% year on year), EBITDA ₹50.0 cr (+61% year on year), PAT ₹30.0 cr (+43% year on year), EBITDA margin 3.6% (+74 bps). Score 80 of 100, Above trend. EBITDA margin rose 74 bps year on year. Consolidated profit +43% but standalone -67%. Not enough history for a trend yet: scored on growth alone. Profit fell 3% from last quarter. Share price after the results: −6.6% in 28 days (Nifty 500: +1.7%).
  • Q4 FY25: Revenue ₹1,339 cr (+30% year on year), EBITDA ₹48.0 cr (+66% year on year), PAT ₹31.0 cr (+48% year on year), EBITDA margin 3.6% (+78 bps). Score 82 of 100, Above trend. EBITDA margin rose 78 bps year on year. Consolidated profit +48% but standalone -173%. Not enough history for a trend yet: scored on growth alone. Share price after the results: −23.5% in 30 days (Nifty 500: +3.1%).
  • Q3 FY25: Revenue ₹1,359 cr (+37% year on year), EBITDA ₹49.0 cr (+75% year on year), PAT ₹29.0 cr (+300% year on year), EBITDA margin 3.6% (+79 bps). Score 91 of 100, Above trend. EBITDA margin rose 79 bps year on year. Not enough history for a trend yet: scored on growth alone.
  • Q2 FY25: Revenue ₹1,301 cr, EBITDA ₹42.0 cr, PAT ₹26.0 cr, EBITDA margin 3.2%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹1,301 cr). Scored once a year-earlier consolidated quarter exists.

Past price moves after results do not indicate future moves. Not a recommendation.

Entero Healthcare Solutions Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.